Precision medicine promises the “right drug, right patient” mantra. One piece that sometimes goes missing? A test approved on day one. Jane Li has spent two decades making sure that gap closes on schedule. As senior director of pharma CDx and CRO partnerships at Thermo Fisher Scientific, she has an important role in this complex…
Navigating the cancer progression pathway with liquid biopsy
Tumor heterogeneity analysis is a challenging but critical step for the advancement of cancer therapy research. DNA mutation interrogation and gene expression pattern evaluation are crucial for predicting a tumor’s response or resistance to specific drug or hormone treatments. Liquid biopsy has emerged as a promising tool, offering a rapid, minimally invasive method for early…